Scancell (LON:SCLP) Shares Up 5.1% - What's Next?

Key Points

• Scancell Holdings plc saw a share price increase of 5.1%, reaching a high of GBX 10.50 during trading, with over 9.8 million shares changing hands, a significant rise from its average volume.
• The company has a debt-to-equity ratio of -566.79, indicating no debt, and a market capitalization of £112.27 million, enhancing its attractiveness to investors.
• Insider Martin Diggle purchased nearly 45,000 shares at an average price of GBX 9, reflecting insider confidence in the firm's growth potential.

Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price traded up 5.1% on Friday . The stock traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). 9,863,690 shares changed hands during mid-day trading, an increase of 953% from the average session volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Price Performance

The stock's 50 day moving average is GBX 9.93 and its two-hundred day moving average is GBX 9.44. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock has a market capitalization of £120.14 million, a PE ratio of -17.78 and a beta of 0.35.

Insider Buying and Selling

In other Scancell news, insider Martin Diggle acquired 4,400,000 shares of the stock in a transaction dated Friday, August 1st. The stock was acquired at an average cost of GBX 10 ($0.13) per share, with a total value of £440,000 ($584,795.32). 4.96% of the stock is owned by company insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.